NASDAQ:ONVO - Organovo Stock Price, Forecast & News

Organovo's stock was trading at $0.26 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ONVO stock has increased by 2.2% and is now trading at $0.2656. View which stocks have been mosted impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organovo in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Organovo.

Organovo is scheduled to release its next quarterly earnings announcement on Monday, June 1st 2020. View our earnings forecast for Organovo.

Organovo Holdings Inc (NASDAQ:ONVO) posted its earnings results on Thursday, August, 8th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.05). The medical research company earned $0.67 million during the quarter, compared to analysts' expectations of $0.77 million. Organovo had a negative return on equity of 69.36% and a negative net margin of 798.68%. View Organovo's earnings history.

Media coverage about ONVO stock has trended very negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Organovo earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutOrganovo.

Organovo saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 2,286,300 shares, an increase of 14.9% from the February 27th total of 1,990,000 shares. Based on an average daily volume of 404,600 shares, the short-interest ratio is currently 5.7 days. Currently, 1.8% of the company's shares are short sold. View Organovo's Current Options Chain.

Some companies that are related to Organovo include Dyadic International (DYAI), Windtree Therapeutics (WINT), Vaxart (VXRT), Brainstorm Cell Therapeutics (BCLI), Fennec Pharmaceuticals (FENC), Solid Biosciences (SLDB), Cidara Therapeutics (CDTX), Erytech Pharma (ERYP), LogicBio Therapeutics (LOGC), Champions Oncology (CSBR), AIM ImmunoTech (AIM), Neon Therapeutics (NTGN), Gamida Cell (GMDA), Axcella Health (AXLA) and Pluristem Therapeutics (PSTI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), Aerojet Rocketdyne (AJRD), NVIDIA (NVDA), Blackstone Group (BX), LADENBURG THALM/SH SH (LTS), Exelixis (EXEL), Micron Technology (MU), Anavex Life Sciences (AVXL), Novavax (NVAX) and General Electric (GE).

Organovo trades on the NASDAQ under the ticker symbol "ONVO."

Shares of ONVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ONVO stock can currently be purchased for approximately $0.27.

Organovo has a market capitalization of $34.66 million and generates $3.09 million in revenue each year. Organovo employs 70 workers across the globe. View additional information about Organovo.

The official website for Organovo is http://www.organovo.com/.

Organovo's mailing address is 440 STEVENS AVE SUITE 200, SOLANA BEACH CA, 92075. The medical research company can be reached via phone at 858-224-1000 or via email at [email protected]